PRME logo

PRME Prime Medicine, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$3.55
-0.29 (-7.55%)

Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA pl…

Market Cap: $645.82Mwww.primemedicine.com

Price

No data yet.

Social Signal Score

53
5d
—
30d
65
2 mentions
—
60d
46
6 mentions
—
90d
48
9 mentions
—
news: 9

Analyst Ratings

10 analysts
Buyconsensus
Strong Buy 0Buy 7Hold 3Sell 0Strong Sell 0
Avg price target$7.5+111.3%
Low $6Median $7.5High $9
Current Consensus

Revenue

$4.21M
$0.00$1.40M$2.81M$4.21M
Dec 2019Sep 2026

Analyst Estimates

FY2025
$-1.34
$-1.46–$-1.13
8 analysts
FY2026
$-0.96
$-1.06–$-0.82
9 analysts
FY2027
$-0.86
$-1.05–$-0.70
10 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Allan Reine
Sector
Healthcare
Industry
Biotechnology
Employees
146
Beta
2.15
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
-7.31
www.primemedicine.com